抗体依赖性细胞介导的细胞毒性
免疫学
抗体
免疫疗法
免疫系统
细胞毒性
自然杀伤细胞
癌症
抗原
癌症免疫疗法
免疫原性
生物
Fc受体
嵌合抗原受体
癌症研究
单克隆抗体
体外
生物化学
遗传学
作者
Sheena Pinto,Jens Pahl,Arndt Schottelius,Paul J. Carter,Joachim Koch
标识
DOI:10.1016/j.it.2022.09.007
摘要
Bi-, tri- and multispecific antibodies have enabled the development of targeted cancer immunotherapies redirecting immune effector cells to eliminate malignantly transformed cells. These antibodies allow for simultaneous binding of surface antigens on malignant cells and activating receptors on innate immune cells, such as natural killer (NK) cells, macrophages, and neutrophils. Significant progress with such antibodies has been achieved, particularly in hematological malignancies. Nevertheless, several major challenges remain, including increasing their immunotherapeutic efficacy in a greater proportion of patients, particularly in those harboring solid tumors, and overcoming dose-limiting toxicities and immunogenicity. Here, we discuss novel antibody-engineering developments designed to maximize the potential of NK cells by NK cell engagers mediating antibody-dependent cellular cytotoxicity (ADCC), thereby expanding the armamentarium for cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI